Drugs / DFP-10917
DFP-10917
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06382168 | Jun 2024 → Mar 2026 overdue | acute myeloid leukemia | Delta-Fly Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01702155 | Oct 2012 → Jan 2017 | acute lymphoblastic leukemia, acute myeloid leukemia | Delta-Fly Pharma, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03926624 | Nov 2019 → Jan 2026 | acute myeloid leukemia | Delta-Fly Pharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFP-10917 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01702155 ↗ |
| Known as | 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride | “DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride” NCT03926624 ↗ |
| Route | Intravenous | “14-day continuous intravenous infusion” PMID 30668890 ↗ Jan 2019 |